ChemicalBook CAS DataBase List 950834-06-7

950834-06-7

Name	CXL-1020
CAS	950834-06-7
Molecular Formula	C7H9NO5S2
Molecular Weight	251.28
MOL File	950834-06-7.mol

Chemical Properties

form	Solid
color	White to off-white

Hazard Information

Uses

CXL-1020 is a hydroxylamine-based nitroxyl (HNO) donor. CXL-1020 improves cardiac inotropy/lusitropy and Ca2+ cycling in rats with abnormal relaxation. CXL-1020 induces vasorelaxation and improves cardiac function in canine models. CXL-1020 has been used to research systolic heart failure and stable heart failure[1].

in vivo

CXL-1020 (100 μg/kg/min; infusion for 30 min) improves hemodynamics and cardiac function, and enhances both diastolic and systolic performance in mice^[1].
CXL-1020 (3 and 10 mg/kg/min; 4-hour intravenous infusion) improves left ventricular systolic and diastolic function in dogs with advanced heart failure^[2].

Animal Model:	Adult male Sprague-Dawley rats (250-350 g; induced cardiac dysfunction by isoproterenol)^[1]
Dosage:	100 μg/kg/min
Administration:	For 30 min
Result:	Improved hemodynamics and cardiac function in normal rats, and enhanced both diastolic and systolic performance in cardiac dysfunction mice.

Animal Model:	Dogs (coronary microembolization-induced heart failure)^[2] 3 and 10 mg/kg/min
Dosage:	3 and 10 mg/kg/min
Administration:	4-hour intravenous infusion
Result:	Decreased systolic aortic pressure (AoP) modestly; significantly increased EF and deceleration time of early mitral inflow velocity (DT) and significantly lowered left ventricular (LV) end-systolic volume (ESV), LV end-diastolic pressure (EDP) and end-diastolic wall stress (EDWS) in a dose-dependent manner.

IC 50

L-type calcium channel

References

[1] Roof SR, et al. CXL-1020, a Novel Nitroxyl (HNO) Prodrug, Is More Effective than Milrinone in Models of Diastolic Dysfunction-A Cardiovascular Therapeutic: An Efficacy and Safety Study in the Rat. Front Physiol. 2017 Nov 10;8:894. DOI:10.3389/fphys.2017.00894
[2] Mengjun Wang, et al. Intravenous Infusion of CXL-1020, a Novel Nitroxyl (HNO) Donor, Improves Left Ventricular Systolic and Diastolic Function in Dogs with Advanced Heart Failure. CARDIOVASCULAR PHARMACOLOGY. VOLUME 15, ISSUE 6, SUPPLEMENT, S73-S74, AUGUS

Supplier

Send Inquriy